Evaluation of diatrizoate meglumine (Hypaque) in treatment of sudden hearing loss.

Thirty patients with sudden hearing loss were treated with diatrizoate meglumine (Hypaque) and a vasodilator regimen. Of these patients, 30% had a good response, 23% had a moderate response, and 47% had no response. These results were superior to the results obtained in a group of patients with sudden hearing loss treated with vasodilators alone. A possible mode of action is discussed and the details of a new study outlined.